| ID | 1131 |
| Name of the vaccine | Menitorix |
| Microbe | Bacteria |
| Disease name | Meningococcal disease |
| Name of bacteria | Neisseria meningitidis |
| Type of vaccine | Conjugate |
| Nucleic acid content | DNA |
| Age | 2 months to 2 years |
| Description of the vaccine | Haemophilus type b and Meningococcal group C conjugate vaccine. |
| Name of the manufacturer | GlaxoSmithKline Biologicals |
| Name of the manufacturing country | Belgium |
| Year of manufacture | 2005 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram-negative diplococcus. |
| Efficacy | NA |
| Vaccine formulation | Powder and solvent for solution for injection. |
| Dosage | Single injection (0.5 ml). If first vaccination against Hib and MenC : three doses with a gap of at least four weeks.
Booster protection: in the second year of life. |
| Mechanism of action | Works by causing the body to produce its own protection (antibodies) against these bacteria. |
| Route of administration | Intramuscular |
| Indications | Prevents Haemophilus influenzae type b (Hib) and Neisseria meningitidis group C (MenC) bacteria diseases. |
| Export | Marketing Authorisation Holder- SmithKline Beecham Ltd |
| Approval | Member States of the EEA |
| Adjuvant | NA |
| Repurposing | For Haemophilus influenzae type b (Hib). |
| Side effects of vaccine | Pain, redness or swelling at the injection site, fever, irritability, loss of appetite and sleepiness. |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.medicines.org.uk/emc/files/pil.167.pdf |
| Other name | NA |
| Additional Links | https://www.medicines.org.uk/emc/product/167/smpc#gref
|